Neurospector

Brain disorders such as dementia, epilepsy, autism spectrum disorder, and hundreds of rare conditions collectively impact nearly 180 million patients in the European Union alone. A significant challenge in developing effective therapies for these disorders is the lack of predictive model systems, leading to high attrition rates in drug development programs.

Neurospector has developed a pioneering technology that combines the high predictive value of human neuron cell models with scalable tools to evaluate functional parameters of neuronal activity. This approach enables rapid and precise testing of new treatment modalities. Our expertise centers on IPSC-derived patient neurons and gene-edited human neuron disease models, which serve as predictive in vitro systems for drug screening, complemented by live microscopy readouts of neuronal activity.

The Neurospector team is dedicated to valorizing scientific knowledge, turning cutting-edge research into solutions that address critical challenges in the drug development landscape. Our technological developments aim to accelerate the drug discovery process and enhance the likelihood of identifying effective treatments for millions of patients worldwide. Currently, we are focusing on neurodevelopmental disorders such as STXBP1-related disorder, epilepsy, autism spectrum disorder, and motor neuron disorders like ALS/FTD.

Through collaborations with the pharmaceutical industry and academic partners, we strive to fully realize the potential of our research in discovering new treatments for patients. For more information, please visit our website: www.neurospector.com, or contact us for more information.